Acta Scientific Neurology (ASNE) (ISSN: 2582-1121)

Review Article Volume 3 Issue 10

Publication Pattern of Clinical Parkinson’s Disease Research in Saudi Arabia

Naïf Alotibe1, Eman Nasim1, Talal Harbi1, Raunaq Saba Ali2, Muhammad Al Firdausi3, Shafiq Ahmad3 and Shahid Bashir1*

1Neuroscience Center, King Fahad Specialist Hospital, Dammam, Saudi Arabia
2Department of Bioinformatics and Bioscience, COMSATS Institute of Information Technology (CIIT), Pakistan
3Industrial Engineering Department, King Saud University Riyadh, Saudi Arabia

*Corresponding Author: 3Industrial Engineering Department, King Saud University Riyadh, Saudi Arabia

Received: August 19, 2020; Published: September 26, 2020



Objective: To assess the progress in the field clinical Parkinson’s disease (PD) in kingdom of Saudi Arabia (KSA), by analyzing in depth the research output productivity and publication pattern, and to identify the current situation of PD research and offer solutions.

Method: Literature search strategy was designed to retrieve accessible articles that are related to PD utilizing PubMed, Google Scholar, and Embase. The retrieved articles were analyzed with several parameters including “journal name, impact factor, year of publication, the affiliation of the first author, city, study design, population, citation numbers, study title and database”.

Results: Of all identified articles, 41 were conducted in KSA and therefore were included. The included articles had a frequency of only 0.52% publications from 1992-2011, and growth of 75.6% between the periods of 2012-2020. Only 5% of the articles were related to surgical options to treatment of PD but the majority (95%) were related to medical treatment of PD. The most common study design was retrospective studies in 27.27%.

Conclusion: Pattern of publications in PD researches revealed a slow growth rate in the frequency and a lower significance in the quality throughout the past 28 years. Active institutional and national promotion of clinical research is needed to help assess and therefore improve the quality of the provided PD services.

Keywords: Parkinson’s Disease; Parkinsonism; Levodopa; Movement Disorders; Neurodegenerative; Bradykinesia



  1. Al-Bunyan MA. “Parkinson`s disease. Clinical and electrophysiology evaluation”. Neurosciences (Riyadh)1 (2000): 46-49.
  2. Bohlega S., et al. “Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience”. European Neurology 74 (2015): 227-236.
  3. Chishti MA., et al. “T313M PINK1 mutation in an extended highly consanguineous Saudi family with early-onset Parkinson disease”. Archives of Neurology10 (2006): 1483-1485.
  4. Al-Omari FA., et al. “Oral rehabilitation of Parkinson's disease patient: a review and case report”. Case Reports on Dentistry (2014): 432475.
  5. Dirk Deleu., et al. “Current and emerging strategies in the management of Parkinson’s disease: a critical reappraisal”. Saudi Medical Journal2 (1997): 115-126
  6. Rana AQ., et al. “Association between nocturia and anxiety in Parkinson's disease”. Neurology Research7 (2015): 563-567.
  7. El-Sadik AO. “Potential sources of stem cells as a regenerative therapy for Parkinson's disease”. Stem Cells Cloning 3 (2010): 183-191.
  8. Riyazuddin Shamsul Haq Ansari and Hany Murtada Al Hasan. "Parkinson’s Disease with Sigmoid Volvulus”. International Journal of Case Reports in Medicine (2013).
  9. H Alaskar and A Hussain. "Prediction of Parkinson Disease Using Gait Signals”. 11th International Conference on Developments in eSystems Engineering (DeSE), Cambridge, United Kingdom (2018): 23-26.
  10. Awada A., et al. “Outpatient neurological practice in Saudi Arabia and its implications for education in neurology”. Annals of Saudi Medicine 5 (1992): 503-505.
  11. M Alhussein. "Monitoring Parkinson’s Disease in Smart Cities”. in IEEE Access 5 (2017): 19835-19841
  12. Jones AC., et al. “Autosomal recessive juvenile parkinsonism maps to 6q25.2-q27 in four ethnic groups: detailed genetic mapping of the linked region”. American Journal of Human Genetics 1 (1998): 80-87.
  13. Al-Tawfiq JA., et al. “Sterile cyst formation after intrathecal stem cell transplant for Parkinson's disease: A case presentation and literature review”. Journal of Infection and Public Health 4 (2015): 382-385.
  14. Bohlega SA and Al-Foghom NB. “Drug-induced Parkinson`s disease. A clinical review”. Neurosciences (Riyadh)3 (2013): 215-221.
  15. Yemni EA., et al. “Integrated Analysis of Whole Exome Sequencing and Copy Number Evaluation in Parkinson's Disease”. Scientific Report1 (2019): 3344.
  16. Alamri Y., et al. “Parkinson's Disease in the Gulf Countries: An Updated Review”. European Neurology 74 (2015): 222-225.
  17. Fouly RT., et al. “Knowledge of Saudi Population about Parkinson Disease”. International Journal of Innovative Research in Medical Science1 (2020): 49-51.
  18. Abdulrahman Muallith Alsuhaymi. “Compliance among parkinsonism in al-madinah region” (2020).
  19. Alamri Y., et al. “Anxiety and depression in Parkinson's disease patients in Saudi Arabia Global neurology”. Journal of the Neurological Sciences 358 (2015): 457-458.
  20. AlSwaiti FY., et al. “The Parkinson's Disease and Movement Disorders Program at King Fahad Medical City” (2015).
  21. Alzahrani H., et al. “Apathy in Mild Parkinson's Disease: Neuropsychological and Neuroimaging Evidence”. Journal of Parkinson's Disease 4 (2016): 821-832.
  22. Al-Mubarak BR., et al. “Parkinson's Disease in Saudi Patients: A Genetic Study”. PLoS One8 (2015): e0135950.
  23. Bohlega SA., et al. “Clinical heterogeneity of PLA2G6-related Parkinsonism: analysis of two Saudi families”. BMC Research Notes 9 (2016): 295.
  24. Jabir NR., et al. “Synopsis on the linkage of Alzheimer's and Parkinson's disease with chronic diseases”. CNS Neuroscience and Therapeutics 1 (2015): 1-7.
  25. Ansari SA., et al. “Current surgical treatment of Parkinson's disease”. Saudi Medical Journal 11 (2002): 1319-1323.
  26. Ahmed MR., et al. “Neuroprotective role of chrysin in attenuating loss of dopaminergic neurons and improving motor, learning and memory functions in rats”. International Journal of Health Sciences (Qassim)3 (2018): 35-43.
  27. Perumal V., et al. “Instruction prioritization in task-based balance training for individuals with idiopathic Parkinson's disease”. Somatosensory Research 1 (2017): 27-33.
  28. Alyamani AM., et al. “Public knowledge and awareness about Parkinson's disease in Saudi Arabia”. Journal of Family Medicine and Primary Care 6 (2018): 1216-1221.
  29. Alghamdi BS. “The neuroprotective role of melatonin in neurological disorders”. Journal of Neuroscience Research 7 (2018): 1136-1149.
  30. Khalil H and Bajwa JA. “Barriers and Facilitators in Physical Rehabilitation for Parkinson's Disease in the Arabian World”. Movement Disorders Clinical Practice 3 (2015): 227-229.
  31. Orayj K and Lane E. “Patterns and Determinants of Prescribing for Parkinson's Disease: A Systematic Literature Review”. Parkinsons Disease (2019): 9237181.
  32. Khalil H., et al. “Parkinson's disease in the MENASA countries”. Lancet Neurology4 (2020): 293-294.
  33. Benamer HT., et al. “Parkinson's disease in Arabs: a systematic review”. Movement Disorder9 (2008): 1205-1210.
  34. Moro E., et al. “Unilateral pedunculopontine stimulation improves falls in Parkinson's disease”. Brain 133 (2010): 215-224.
  35. Mushtaq G., et al. “miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease”. Medicinal Chemistry 3 (2016): 217-225.
  36. Parnetti L., et al. “Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease”. Frontiers in Aging Neuroscience 6 (2014): 53.
  37. Tabrez S., et al. “A synopsis on the role of tyrosine hydroxylase in Parkinson's disease”. CNS and Neurological Disorders - Drug Targets 4 (2012): 395-409.
  38. Karlsson F., et al. “Deep brain stimulation of caudal zona incerta and subthalamic nucleus in patients with Parkinson's disease: effects on diadochokinetic rate”. Parkinsons Disease (2011): 605607.
  39. Soursou G., et al. “Applications of Nanotechnology in Diagnostics and Therapeutics of Alzheimer's and Parkinson's Disease”. Current Drug Metabolism 8 (2015): 705-712.
  40. Al-Amri JS., et al. “Effect of epigallocatechin-3-gallate on inflammatory mediators release in LPS-induced Parkinson's disease in rats”. Indian Journal of Experimental Biology 5 (2013): 357-362.
  41. Zaitone SA., et al. “Caffeic acid improves locomotor activity and lessens inflammatory burden in a mouse model of rotenone-induced nigral neurodegeneration: Relevance to Parkinson's disease therapy”. Pharmacological Reports 1 (2019): 32-41.


Citation: Shahid Bashir., et al. “Publication Pattern of Clinical Parkinson’s Disease Research in Saudi Arabia". Acta Scientific Neurology 3.10 (2020): 48-55.


Acceptance rate32%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US